Earnings Release • Jan 24, 2025
Earnings Release
Open in ViewerOpens in native device viewer
Ad hoc announcement pursuant to Art. 53 LR
EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Results
BB Biotech AG closes the 2024 fiscal year with a profit
24-Jan-2025 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
January 24, 2025
BB Biotech AG closes the 2024 fiscal year with a profit
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information:
Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a profit of approximately CHF 76 million for the financial year 2024 (loss of CHF 207 million in the previous year). For an investment company, the results reflect the share price development of the companies held in the portfolio.
The publication of all relevant portfolio data will take place on January 24, 2025 at 7:00am and the complete annual report will be published on February 21, 2025.
For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00
Head Investment Management Team BB Biotech
Dr. Christian Koch
Investor Relations
Dr. Silvia Siegfried-Schanz, [email protected]
Maria-Grazia Alderuccio, [email protected]
Claude Mikkelsen, [email protected]
Media Relations
Tanja Chicherio, [email protected]
Company profile
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.
End of Inside Information
24-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | [email protected] |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
| EQS News ID: | 2073701 |
| End of Announcement | EQS News Service |
2073701 24-Jan-2025 CET/CEST
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.